News and Press Releases
53Biologics Awarded Best Company in Biotechnology Innovation at Farmaforum
This award acknowledges the company’s groundbreaking work in microbial expression systems and its ongoing commitment to delivering cutting-edge biotechnological solutions for the global market. 53Biologics, a Contract Development and Manufacturing...
Category: Biotechnology
Posted: October 30, 2024
PCI Pharma Services Wins Supply Chain Excellence Award for Groundbreaking Digital Platform to Manage Clinical Trials and Commercial Lifespans
Leading CDMO’s pci | bridge enhances supply chain visibility and reduces time spent on manual activities such as forecasting, inventory management, reporting, supplier management and document sharing. 30 October 2024...
Category: Biotechnology, Clinical Trials, Drug Discovery, Logistics
Posted: October 30, 2024
Rentschler Biopharma announces largest single investment at its headquarters in Germany
Construction of a new buffer media facility in Laupheim Largest investment in the German site; project duration of approx. three years Continuous modernization, automation, and digitalization of the site. 24...
Category: Biotechnology, Manufacturing and Packing, Other
Posted: October 24, 2024
BioPharma Industry Excited about the early use of AI in clinical trials
Experts discuss the long road for complete AI-led transformation at Indegene Digital Summit 202421 October 2024 -- New Jersey, US, and London, UK -- Clinical development experts from Novartis, GSK,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 21, 2024
SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating the Company’s Lead Development Program SR-878
Transition into clinical-stage development marks a significant corporate and R&D milestone 17 October 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 17, 2024
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease OKYO is the first company to have an IND application granted by...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 16, 2024
HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high,clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer MET is a common biomarker in this setting for patients who develop resistance...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 16, 2024
Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia gravis in the Phase 2/3 study
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied 15...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 15, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
14 October 2024 -- Massachusetts, US, and Montreal, Canada -- Repare Therapeutics Inc, a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s Phase...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 14, 2024
Redx Presents Preclinical Data on RXC008, a Potential First-in-Class Therapy to Treat Fibrostenotic Crohn’s Disease, at the UEG Week
Presentation submission wins Top Abstract Prize The oral presentation, entitled “RXC008: First-in-Class Gastrointestinal-Targeted Potent Pan-ROCK Inhibitor for Treatment of Fibrostenotic Crohn’s Disease”, was delivered on Monday 14 October, during the...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: October 14, 2024
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK
Ingenza announces move to purpose-built facilities to expand fermentation and research capacity
1 October 2024 – Roslin, Scotland – Ingenza – a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator – is delighted to announce its plans to relocate...
Category: BioManufacturing
Posted: October 14, 2024
Ingenza Ltd, Roslin Innovation Centr,e Charnock Bradley Building, Easter Bush Campus, Bush Farm Road, Roslin, EH25 9RG, UK
3PBIOVIAN strengthens its leadership team with the appointment of a Business Development Director for Advanced Therapies
This strategic hire will further solidify 3PBIOVIAN’s position as a leading CDMO in the development of advanced therapies and enhance its international commercial team October 9, 2024 – Noáin, Spain–...
Category: BioManufacturing
Posted: October 11, 2024
WCG Releases 2024 Report on Top Issues Impacting Clinical Research Sites
8 October 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve the quality and efficiency of clinical research, today released the WCG 2024 Clinical Research...
Category: Clinical Trials, Other, Pharmaceutical
Posted: October 8, 2024
BD and ten23 health Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes
Innovative RFID-based solution for prefillable syringes (PFS) aims to enhance efficiency and improve traceability during the fill & finish process and product distribution 7 October 2024 -- New Jersey, US,...
Category: BioManufacturing, Drug Delivery, Pharmaceutical
Posted: October 7, 2024
Scotland first in the UK to recommend a new treatment option for lung cancer, which could help lower the risk of cancer returning
7 October 2024 -- Scotland, UK -- the Scottish Medicines Consortium has recommended MSD's KEYTRUDA® (pembrolizumab) as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma (NSCLC)...
Category: Other, Pharmaceutical
Posted: October 7, 2024
